Form 8-K - Current report:
SEC Accession No. 0001551152-25-000006
Filing Date
2025-01-10
Accepted
2025-01-10 08:31:46
Documents
14
Period of Report
2025-01-09
Items
Item 2.06: Material Impairments

Document Format Files

Seq Description Document Type Size
1 8-K abbv-20250109.htm   iXBRL 8-K 38118
  Complete submission text file 0001551152-25-000006.txt   244926

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abbv-20250109.xsd EX-101.SCH 3732
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT abbv-20250109_def.xml EX-101.DEF 19670
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abbv-20250109_lab.xml EX-101.LAB 35780
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abbv-20250109_pre.xml EX-101.PRE 20331
16 EXTRACTED XBRL INSTANCE DOCUMENT abbv-20250109_htm.xml XML 8573
Mailing Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064
Business Address 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 (847) 932-7900
AbbVie Inc. (Filer) CIK: 0001551152 (see all company filings)

EIN.: 320375147 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35565 | Film No.: 25520585
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)